Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Market Analysis and Insights: Global Benign Prostatic Hyperplasia (BPH) Drugs Market
In 2019, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was US$ 3321 million and it is expected to reach US$ 3482.1 million by the end of 2026, with a CAGR of 0.9% during 2021-2026.
Global Benign Prostatic Hyperplasia (BPH) Drugs Scope and Market Size
Benign Prostatic Hyperplasia (BPH) Drugs market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia (BPH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2015-2026.

Segment by Type, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.

Segment by Application, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape

and Benign Prostatic Hyperplasia (BPH) Drugs Market Share Analysis
Benign Prostatic Hyperplasia (BPH) Drugs market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Details included are company description, major business, Benign Prostatic Hyperplasia (BPH) Drugs product introduction, recent developments, Benign Prostatic Hyperplasia (BPH) Drugs sales by region, type, application and by sales channel.

The major companies include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

Frequently Asked Questions